乳腺癌保乳术后1~3个腋窝淋巴结阳性者锁骨上淋巴结复发风险分析

doi:10.3760/cma.j.issn.1004-4221.2015.02.000

摘要
图/表
参考文献()
相关文章 (9)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的分析乳腺癌保乳术后1~3个腋窝淋巴结阳性患者锁骨上淋巴结复发率(SCFR)及高危因素。方法回顾分析2001—2014年本院收治的保乳术+腋窝淋巴结清扫术后乳腺癌患者,病理证实1~3个腋窝淋巴结阳性,无内乳和锁骨上淋巴结转移或远处转移。256例均行全乳腺放疗,剂量46~50 Gy (2 Gy/次)或43.5 Gy (2.9 Gy/次),瘤床总剂量50~70 Gy。245例接受了辅助化疗,45例Her-2受体阳性者18例接受曲妥珠单抗治疗。Kaplan-Meier法计算同侧SCFR、LRR、DM及OS,并Logrank法检验。结果随访时间满5年的样本量为101例。全组5年SCFR、LRR、DM、OS分别为2.1%、2.1%、5.0%、98.0%,2~3个腋窝淋巴结阳性(P= 0.010)、脉管瘤栓(P= 0.030)、LuminalB型(P= 0.006)为锁骨上淋巴结复发的高危因素。腋窝淋巴结阳性数为2~3个和1个者的5年SCFR分别为5.3%和2.8%(P=0.010);脉管瘤栓阳性和阴性的5年SCFR分别为5.3%和1.8%(P=0.030);Luminal B型、三阴性、Luminal A型和Her-2阳性型的5年SCFR分别为7.1%、3.2%、1.2%和0%(P=0.006)。有0、1、2~3个高危因素患者的5年SCFR分别为0%、3.0%、10.6%(P=0.000)。结论在接受现代化疗前提下,乳腺癌保乳术后1~3个腋窝淋巴结阳性者SCFR较低,不需要全部行锁骨上区预防照射。有高危因素患者是否行预防性锁骨上区照射需进一步研究。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李帅
	王淑莲
	李晔雄
	宋永文
	王维虎
	金晶
	刘跃平
	房辉
	任骅
	刘新帆
	余子豪

关键词 ：乳腺肿瘤/术后放射疗法, 乳腺肿瘤/保乳术, 锁骨上淋巴结复发

Abstract：Objective To evaluate the supraclavicular nodal failure (SCF) of the breast cancer patients with one to three positive axillary nodes treated with breast conserving surgery and to identify the risk factors for SCF. Methods From Jan. 2001 to Mar. 2014, 256 breast cancer patients with one to three positive axillary nodes treated with breast conserving surgery and axillary dissection were analyzed. All patients received whole breast radiation to a total dose of 46－50 Gy (median 50 Gy) at 2 Gy/f or 43.5 Gy at 2.9 Gy/f. Tumor bed was boosted to 50－70 Gy (median 60 Gy) at 2 Gy/f or 52.2 Gy at 2.9 Gy/f. No patient received regional nodal radiation. 245(95.7%) patients received adjuvant chemotherapy. The SCF, LRR, DM and OS rates were calculated by Kaplan-Meier method and compare by the Logrank test. Results The number of samples were 101 followed up at 5 years. The 5-year SCF, LRR, DM and OS rates were 2.1%, 2.1%, 5%, 98%, respectively. LVI and 2 to 3 positive axillary node and Luminal B were risk factors for SCF (P=0.030,0.010,0.006). The 5-year SCF rate were 5.3% for patients with 2－3 positive axillary nodes and 2.8% for those with 1 positive nodes (P=0.010);5.3% and 1.8% for those LVI positive and negative (P=0.030);7.1%, 3.2%, 1.2% and 0% for Luminal B, Basal, Luminal A and Her-2 positive type (P=0.006). Patients with 0, 1 and2-3 risk factors had 5 year SCF rates of 0%, 3.0% and 10.6%(P=0.000). Conclusions The supraclavicular nodal recurrence rate is very low for breast cancer patients with one to three positive axillary nodes treated with breast conserving surgery without supraclavicular nodal radiation, indicating that prophylactive supraclavicular nodal is not necessary. Further research is needed to verify whether those patients with risk factors need SCF radiation or not.

Key words： Breast neoplasm/postoperative radiotherapy Breast neoplasm/breast conserving surgery Supraclavicular nodal failure

收稿日期: 2014-12-13

通讯作者: 李晔雄，Email:yexiong12@163.com;王淑莲，Email:wsl20040118@yahoo.com

引用本文:

李帅,王淑莲,李晔雄等. 乳腺癌保乳术后1~3个腋窝淋巴结阳性者锁骨上淋巴结复发风险分析[J]. 中华放射肿瘤学杂志, 2015, 24(2): 149-153.

Li Shuai,Wang Shulian,Li Yexiong et al. Risk factors for supraclavicular nodal failure in breast cancer patients with one to three positive axillary nodes treated with breast conserving surgery[J]. Chinese Journal of Radiation Oncology, 2015, 24(2): 149-153.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2015.02.000 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2015/V24/I2/149

[1]Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomised trials[J].Lancet,2005,366(9503):2087-2106.
[2]Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer[J].N Engl J Med,2002,347(16):1227-1232.
[3]NCCN. Version3.2014[DB/OL][2014-12-10].http://www. NCCN.org.
[4]Budach W, Kammers K, Boelke E, et al. Adjuvant radiotherapy of regional lymph nodes in breast cancer-a meta-analysis of randomized trials[J/OL]. Radiat Oncol,2013,8:267[2014-12-10].http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842771/.DOI:10.1186/1748－717X-8-267.
[5]Fodor J, Toth J, Major T, et al. Incidence and time of occurrence of regional recurrence in stage Ⅰ－Ⅱ breast cancer:value of adjuvant irradiation[J].Int J Radiat Oncol Biol Phys,1999,44(2):281-287.
[6]Galper S, Recht A, Silver B, et al. Factors associated with regional nodal failure in patients with early stage breast cancer with 0－3 positive axillary nodes following tangential irradiation alone[J].Int J Radiat Oncol Biol Phys,1999,45(5):1157-1166.
[7]Livi L, Scotti V, Saieva C, et al. Outcome after conservative surgery and breast irradiation in 5,717 patients with breast cancer:implications for supraclavicular nodal irradiation[J]. Int J Radiat Oncol Biol Phys, 2010,76(4):978-983. DOI:10.1016/j.ijrobp.2009.03.001.
[8]Reddy SG Kiel KD. Supraclavicular nodal failure in patients with one to three positive axillary lymph nodes treated with breast conserving surgery and breast irradiation, without supraclavicular node radiation[J]. Breast J,2007,13(1):12-8.
[9]Yates L, Kirby S, Crichton S, et al. Risk factors for regional nodal relapse in breast cancer patients with one to three positive axillary nodes[J]. Int J Radiat Oncol Biol Phys. 2012,82(5):2093-2103.DOI:10.1016/j.ijrobp.2011.01.066.11 Apr 27.
[10]Aristei C, Leonardi C, Stracci F, et al. Risk factors for relapse after conservative treatment in T₁-T₂ breast cancer with one to three positive axillary nodes:results of an observational study[J]. Ann Oncol,2011,22(4):842-847.DOI:10.1093/annonc/mdq470.
[11]Fisher B, Costantino J, Redmond C, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors[J].N Engl J Med,1989,320(8):479-484.
[12]Buchholz TA, Tucker SL, Erwin J, et al. Impact of systemic treatment on local control for patients with lymph node-negative breast cancer treated with breast-conservation therapy[J].J Clin Oncol,2001,19(8):2240-2246.
[13]Coen JJ, Taghian AG, Kachnic LA, et al. Risk of lymphedema after regional nodal irradiation with breast conservation therapy[J].Int J Radiat Oncol Biol Phys,2003,55(5):1209-1215.
[14]Kahan Z, Csenki M, Varga Z, et al. The risk of early and late lung sequelae after conformal radiotherapy in breast cancer patients[J].Int J Radiat Oncol Biol Phys,2007,68(3):673-681.
[15]Matzinger O, Heimsoth I, Poortmans P, et al. Toxicity at three years with and without irradiation of the internal mammary and medial supraclavicular lymph node chain in stage Ⅰ to Ⅲ breast cancer (EORTC trial 22922/10925)[J].Acta Oncol, 2010,49(1):24-34.DOI:10.3109/02841860903352959.
[16]Truong PT, Jones SO, Kader HA, et al. Patients with t1 to t2 breast cancer with one to three positive nodes have higher local and regional recurrence risks compared with nogative patients after breast-conserving surgery and whole-breast radiotherapy[J].Int J Radiat Oncol Biol Phys,2009,73(2):357-364.DOI:10.1016/j.ijrobp.2008.04.034.
[17]Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer:highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2013[J].Ann Oncol,2013,24(9):2206-2223.DOI:10.1093/annonc/mdt303.
[18]Perou CM,Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours[J].Nature,2000,406(6797):747-752.
[19]Olivotto IA, Chua B, Elliott EA, et al. A clinical trial of breast radiation therapy versus breast plus regional radiation therapy in early-stage breast cancer:the MA20 trial[J].Clin Breast Cancer,2003,4(5):361-363.
[20]Yu JI, Park W, Huh SJ, et al. Determining which patients require irradiation of the supraclavicular nodal area after surgery for N₁ breast cancer[J].Int J Radiat Oncol Biol Phys,2010,78(4):1135-1141.DOI:10.1016/j.ijrobp.2009.09.037.
[21]Wo JY, Taghian AG, Nguyen PL, et al. The association between biological subtype and isolated regional nodal failure after breast-conserving therapy[J].Int J Radiat Oncol Biol Phys, 2010,77(1):188-196.DOI:10.1016/j.ijrobp.2009.04.059.
[22]Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer[J].N Engl J Med,2005,353(16):1673-1684.
[23]Slamon D, Eiermann W, Robert N, et al. Adjuvant trastuzumab in HER2-positive breast cancer[J].N Engl J Med,2011, 365(14):1273-1283.
[24]Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer:a randomised controlled trial[J].Lancet,2007,369(9555):29-36.
[25]Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer:planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831[J].J Clin Oncol,2014,32(33):3744-3752.DOI:10.1200/JCO.2014.55.5730.
[26]Freedman GM,Anderson PR, Li T, et al. Locoregional recurrence of triple-negative breast cancer after breast-conserving surgery and radiation[J].Cancer,2009,115(5):946-951.DOI:10.1002/cncr.24094.